News & Events
International Workshop Focuses on Defining Prodromal Phases of ALS, FTD
May 2, 2023
Michael Benatar, M.D., Ph.D., at the University of Miami organized and hosted the Second International Pre-Symptomatic ALS Workshop on February 27, 2023, which focused on defining the prodromal stages of …
Read moreNew Grants Support Six Projects with ‘Ambitious Goal’ of Preventing ALS
February 16, 2023
Read the full update at the link below. View update
Read moreDealing ALS a New Hand
December 7, 2022
Research reveals clues that may enable treatment even before symptoms show. Read the full article at the link below. View Article
Read moreMiller School Studies Pave the Way for the First Pre-Symptomatic ALS Trial for Individuals with SOD1 Genetic Mutation
May 7, 2021
For more than a decade, investigators at the University of Miami Miller School of Medicine have been studying the earliest signs of amyotrophic lateral sclerosis (ALS). Now, armed with biomarkers …
Read moreUM Researchers’ Validation of ALS Biomarker Could Accelerate Development of New Therapies
May 6, 2020
Researchers at the University of Miami Miller School of Medicine have validated a biomarker for amyotrophic lateral sclerosis (ALS) – a finding that could lead to faster and more efficient …
Read moreALS Center investigators host first international Pre-Symptomatic ALS Workshop
February 9, 2020
The first Pre-Symptomatic ALS Workshop, organized and hosted by Dr. Michael Benatar (University of Miami), took place in Miami on January 27th, 2020. This Workshop brought together ~40 specialists in …
Read moreCReATe Consortium Aims for ALS Breakthroughs with NIH Renewal Grant
October 4, 2019
An international research consortium led by investigators at the University of Miami Miller School of Medicine has made significant progress in understanding amyotrophic lateral sclerosis (ALS) and related diseases since …
Read morePhase III Trial Evaluating Arimoclomol for ALS Patients Reaches Full Enrollment
July 18, 2019
An international phase III clinical trial evaluating the drug Arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) has reached full enrollment, as reported by a University of Miami Miller …
Read more